Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.
Peter Godsk JørgensenMagnus T JensenPernille MensbergHeidi StorgaardSigne NybyJan S JensenFilip K Krag KnopTina VilsbøllPublished in: Diabetes, obesity & metabolism (2017)
In patients with type 2 diabetes, both supervised exercise and treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) liraglutide may improve cardiac function. We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin. Early diastolic myocardial tissue velocity was improved by exercise in the placebo group (mean ± standard deviation [s.d.] -7.1 ± 1.6 to -7.7 ± 1.8 cm/s, P = .01), but not in the liraglutide group (-7.1 ± 1.4 to -7.0 ± 1.4 cm/s, P = .60; between groups, P = .02). Similarly, the mean ± s.d. ratio of early and atrial mitral annular tissue velocities improved in the placebo group (1.0 ± 0.4 to 1.2 ± 0.4, P = .003), but not in the liraglutide group (1.0 ± 0.3 to 1.0 ± 0.3, P = .87; between groups, P = .03). We found no significant differences in heart rate, left ventricular (LV) structure or function within or between the groups. In conclusion, the addition of liraglutide to exercise in sedentary patients with dysregulated type 2 diabetes may blunt the suggested beneficial effect of exercise on LV diastolic function.
Keyphrases
- left ventricular
- double blind
- physical activity
- high intensity
- placebo controlled
- clinical trial
- heart rate
- type diabetes
- blood pressure
- resistance training
- phase iii
- rheumatoid arthritis
- machine learning
- mitral valve
- heart failure
- study protocol
- cardiovascular disease
- open label
- randomized controlled trial
- phase ii
- systemic lupus erythematosus
- adipose tissue
- ejection fraction
- body composition
- glycemic control
- idiopathic pulmonary fibrosis
- phase ii study